Daxor DXR 深 沪
等待开盘 10-29 09:30:00 美东时间
8.97
+0.080
+0.90%
华盛通- 最 高9.0499
- 今 开8.76
- 成交量 1.62万股
- 最 低 8.76
- 昨 收 8.89
- 总市值 5236.89万
- 52周最高 14.7578
- 市盈率 静 4.88
- 换手率 0.28%
- 52周最低 8.56
- 委 比 -90.52%
- 总股本 583.82万
- 历史最高 24.076
- 量 比 1.24
- 振 幅 3.26%
- 历史最低 0.00
- 每 手 1
- 风险率 1.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Daxor Corp收跌1.6%，成交额19.87万美元
10月24日，Daxor Corp（DXR）收跌1.6%，报9.25美元，成交额19.87万美元，市值5400.31万美元。 行情数据 • 开盘价：9.68美元...
10-24 07:24
Daxor Corp收跌1.47%，成交额4.54万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:23
Daxor Announces New Clinical Studies Validate BVA Technology In High-Acuity Heart Failure Populations To Enhance Care At HFSA 2026 Annual Scientific Meeting
Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting. Strong clinician engagement at the confere...
10-14 20:08
Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026
Daxor Corporation will debut its BVA technology at ASN Kidney Week 2026 in Denver, showcasing precise blood volume measurement solutions for complex kidney care. The company will exhibit at Booth #390, highlighting BVA's role in addressing fluid management challenges, such as cardiorenal syndrome and dialysis optimization. Daxor aims to advance precision medicine by providing actionable data for safer patient outcomes. Visit their booth to learn ...
10-13 12:00
Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
Daxor Corporation's FDA-cleared next-generation Blood Volume Analyzer (BVA) delivers faster results with less blood, addressing heart failure management. The device operates 3x faster, requires 50% less blood, and achieves >95% accuracy. Daxor will showcase the BVA at the HFSA Annual Scientific Meeting in Phoenix, October 9–12, 2026, with clinical evidence presented on volume derangements in complex heart failure patients. The platform aims to im...
10-01 12:00
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announced that CEO Michael Feldschuh will participate in Lake Street's BIG10 Conference in New York City on September 10, 2026. Management will hold investor meetings, and interested parties can contact Bret Shapiro at CORE IR for more information. Daxor's innovative BVA diagnostic system provides precise blood volume data, improving patient outcomes and efficiency ...
09-08 21:40
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Daxor Corporation provided a mid-year update highlighting strong progress in 2026, including a $9 million capital raise, debt retirement, and investments in manufacturing and sales expansion. The company saw 16% kit sales growth, launched a new sales leadership team, and received interest from over 15 hospitals for its next-generation BVA system. Daxor also secured a new patent for remote blood volume monitoring and strengthened its clinical evid...
09-01 12:00
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Daxor Corporation has received U.S. Patent No. 12,635,917 B2 for a remote blood volume monitoring system that enables continuous, non-invasive tracking of blood volume status using wearable sensors. This technology integrates hematocrit monitoring with Daxor's advanced algorithms to provide real-time updates on total blood volume without repeated tracer injections. The system offers personalized treatment guidance and predictive alerts for condit...
06-02 12:00
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
<p>Daxor Corporation, a leader in blood volume measurement technology, has expanded its operations by launching a new Blood Volume Analysis (BVA) program at a leading cardiology facility in Southwest Ohio. This initiative integrates Daxor’s advanced testing into a high-volume heart failure care setting, targeting the growing market for chronic disease management. The facility now benefits from Daxor’s Tennessee-based ezBVA Lab workflow, enabling ...
04-08 12:00
